SCHEMBL6077534

SCHEMBL6077534

COC(=O)C(O)=CC(=O)N(Cc1ccc(F)cc1)OCC(=O)N(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
TDP1 Q9NUW8 1/20 0.35
KMT2A Q03164 5/20 0.35
MEN1 O00255 3/20 0.35
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RIPK1 Q13546 1/20 0.34
LTA4H P09960 1/20 0.34
OPRM1 P35372 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C8 P10632 1/20 0.33
CYP2B6 P20813 1/20 0.33
FOLH1 Q04609 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6881585 0.90 ALDH1A1 (0.40) ALDH1A1LMNAMAPTTDP1KMT2A
SCHEMBL6881588 0.90 ALDH1A1 (0.40) ALDH1A1LMNAMAPTTDP1KMT2A
SCHEMBL6076879 0.88 CA12 (0.40) ALDH1A1LMNAMAPTCA12CA1
SCHEMBL6076881 0.88 CA12 (0.40) ALDH1A1LMNAMAPTCA12CA1
SCHEMBL6077249 0.84 CA12 (0.42) ALDH1A1CA12CA1CA2CA9
SCHEMBL6077241 0.84 CA12 (0.42) ALDH1A1CA12CA1CA2CA9
SCHEMBL6076961 0.84 NR1D1 (0.38) ALDH1A1LMNAMAPTCA12CA1
SCHEMBL6076970 0.84 NR1D1 (0.38) ALDH1A1LMNAMAPTCA12CA1
SCHEMBL6076427 0.83 CA12 (0.38) CA12CA1CA2CA9TDP1
SCHEMBL6076423 0.83 CA12 (0.38) CA12CA1CA2CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF ALDH1A1 563/4885LMNA 3521/4885MAPT 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.